Alliqua’s (ALQA) “Buy” Rating Reaffirmed at HC Wainwright
Alliqua Inc. (NASDAQ:ALQA)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Friday.
A number of other research firms also recently commented on ALQA. Chardan Capital reaffirmed a “buy” rating on shares of Alliqua in a research note on Sunday, July 10th. Zacks Investment Research raised Alliqua from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a research note on Thursday, August 11th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Alliqua currently has an average rating of “Buy” and an average price target of $2.50.
Alliqua (NASDAQ:ALQA) traded down 3.37% on Friday, reaching $0.86. 116,269 shares of the company’s stock were exchanged. Alliqua has a 52 week low of $0.70 and a 52 week high of $3.82. The company’s market cap is $25.52 million. The stock’s 50 day moving average is $0.91 and its 200 day moving average is $1.00.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/07/alliquas-alqa-buy-rating-reaffirmed-at-hc-wainwright.html
Alliqua (NASDAQ:ALQA) last posted its quarterly earnings results on Tuesday, August 9th. The company reported $0.05 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.32. The business earned $5.50 million during the quarter, compared to the consensus estimate of $5.38 million. Alliqua had a negative return on equity of 53.07% and a negative net margin of 73.41%. On average, equities analysts anticipate that Alliqua will post ($0.72) earnings per share for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALQA. US Bancorp DE boosted its position in Alliqua by 29.8% in the second quarter. US Bancorp DE now owns 181,732 shares of the company’s stock worth $204,000 after buying an additional 41,732 shares in the last quarter. Vanguard Group Inc. boosted its stake in Alliqua by 1.1% in the second quarter. Vanguard Group Inc. now owns 524,296 shares of the company’s stock valued at $587,000 after buying an additional 5,780 shares during the period. Suffolk Capital Management LLC boosted its stake in Alliqua by 18.0% in the second quarter. Suffolk Capital Management LLC now owns 1,206,127 shares of the company’s stock valued at $1,351,000 after buying an additional 184,274 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in Alliqua by 589.0% in the first quarter. Renaissance Technologies LLC now owns 137,800 shares of the company’s stock valued at $113,000 after buying an additional 117,800 shares during the period. Hedge funds and other institutional investors own 29.89% of the company’s stock.
Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.
Receive News & Ratings for Alliqua Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Inc. and related companies with MarketBeat.com's FREE daily email newsletter.